Healthcare
ThermoGenesis Holdings, Inc.(THMO)
Live Price
Offline$0.0001
+0.00% today
1Y Change
+0.00%
Window
Jun 20, 2025 โ Jun 15, 2026
- Market Cap
- โ
- Revenue Growth
- -9.9%
- EPS Growth
- +62.9%
- Dividend Yield
- 0.0%
Coverage: 252 bars ยท Jun 20, 2025 โ Jun 15, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
ThermoGenesis Holdings, Inc. (THMO) is a Healthcare stock with listed on OTC. The stock last traded around $0.00 and up 0.0% across the available one-year price window (Jun 20, 2025 โ Jun 15, 2026). Baseline metrics include revenue growth of -9.9%, EPS growth of +62.9%, a dividend yield of 0.0%. What stands out right now is revenue -9.9%, EPS +62.9%, free cash flow +29.0% with operating margin -69.6% and ROIC -92.3%. Valuation is more restrained than many high-expectation growth names at price/sales 0.0. Overall, the current profile looks closer to a turnaround or cyclical reset than a generic broad-market placeholder. Stock Foundry combines THMO price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Sector Context
How this name stacks up against nearby peers on first-pass metrics.
Revenue Growth
Below sector median
-9.9% vs +7.6% peer median
Operating Margin
Below sector median
-69.6% vs +19.4% peer median
What Changed This Quarter
Latest report context and the signals most likely to have changed the story.
Latest report is on the board
2026 was reported on May 19, 2026, but the surprise data is still limited.
The operating picture looks softer than before
Revenue is at -9.9% and EPS is at +62.9%, with operating margin around -69.6%.
Earnings Reaction Memory
How the stock has tended to move after recent reports.
Across the last 3 reported quarters, the stock averaged 0.0% over the next 5 trading days and finished higher after 0 of those reports.
View quarter-by-quarter reaction table
| Quarter | EPS ฮ | 1D | 5D | 20D |
|---|---|---|---|---|
2026 May 19, 2026 | โ | +0.0% | +0.0% | โ |
2026 Feb 25, 2026 | โ | +0.0% | +0.0% | +0.0% |
2025 Jun 11, 2025 | โ | +0.0% | +0.0% | +0.0% |
Benchmark Comparison
Normalized Performance vs SPY
Compare this ticker against a broad index, growth benchmark, or sector ETF using a shared 1Y normalization window.
THMO
โ
Normalized return
SPY
โ
S&P 500
Excess Return
โ
Relative to SPY
THMO Max Drawdown
0.00%
Trailing 1Y
SPY Max Drawdown
โ
Trailing 1Y
Calendar-Year Returns
Uses the longest available daily history for THMO and SPY.
Company Overview
ThermoGenesis Holdings, Inc.
Other OTC
ThermoGenesis Holdings, Inc. develops, commercializes, and markets a range of automated technologies for cell-banking, cell-processing, and cell-based therapeutics in the United States, China, the United Arab Emirates, Vietnam, and internationally. The company provides medical device products for automated cell processing. Its clinical bio-banking applications include AXP II Automated Cell Separation System, an automated fully closed cell separation system for isolating stem and progenitor cells from umbilical cord blood; and BioArchive Automated Cryopreservation System, an automated, robotic, liquid nitrogen controlled-rate-freezing and cryogenic storage system for cord blood samples and cell therapeutic products used in clinical applications. The company's point-of-care applications include XP Point-of-Care System, an automated, fully closed, sterile system that allows for the rapid and automated processing of autologous peripheral blood or bone marrow aspirate derived stem cells at the point-of-care, such as surgical centers or clinics; and PXP-1000 System, an automated, fully closed system that provides fast, reproducible separation of multiple cellular components from blood with minimal red blood cell contamination. Its cell processing products comprise X-Series products for general laboratory use, such as X-Lab for cell isolation, X-Wash System for cell washing and reformulation, and X-Mini for high efficiency small scale cell purification. The company also provides contract development and manufacturing services for cell and cell-based gene therapies. It markets and sells its medical device products through independent distributors, as well as direct to end-user customers. The company was formerly known as Cesca Therapeutics Inc. and changed its name to ThermoGenesis Holdings, Inc. in November 2019. ThermoGenesis Holdings, Inc. was incorporated in 1986 and is headquartered in Rancho Cordova, California.
- Leadership
- Xiaochun Xu
- IPO Date
- Jun 5, 1987
- Employees
- 25
- Street Address
- 2711 Citrus Road
- Mailing
- Rancho Cordova, CA, 95742
- Region
- Rancho Cordova, CA, US
- Reporting Currency
- USD
- Investor Line
- 916 858 5100
- Last Updated
- May 5, 2026
Key Fundamentals
Valuation, growth, profitability, and balance sheet signals.
Valuation
- P/E
- โ
- EV/EBITDA
- โ
- Price/Sales
- 0.0
- Price/Book
- โ
Growth
- Revenue
- -9.9%
- EPS
- +62.9%
- Free Cash Flow
- +29.0%
Profitability
- Gross Margin
- 20.4%
- Operating Margin
- -69.6%
- Net Margin
- -190.3%
- ROE
- -1367.4%
- ROIC
- -92.3%
Balance Sheet
- Debt/Equity
- โ
- Current Ratio
- 0.44
Earnings Reports
Latest News
Official Releases
Company announcements and filings-style updates.
Next Step
Keep the research moving
After the overview, the strongest next step is usually chart context or a tighter compare set.